The Effects of Different Ciprofol Doses on Hemodynamics During Anesthesia Induction in Patients Undergoing Cardiac Surgery: A Randomized, Double-Blind, Controlled Study.
{"title":"The Effects of Different Ciprofol Doses on Hemodynamics During Anesthesia Induction in Patients Undergoing Cardiac Surgery: A Randomized, Double-Blind, Controlled Study.","authors":"Yingting Zhou, ZiYou Liu, QianQian Li, PengFei Ni, ZuoHui Li, BeiJia Yu, Min Zhang, Jia Yang, YanHu Xie","doi":"10.2147/DDDT.S505772","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the effects of different ciprofol doses on hemodynamics in patients undergoing cardiac surgery.</p><p><strong>Methods: </strong>209 patients were randomly divided into four groups: 0.2 mg/kg etomidate group (group E, n = 50), 0.2 mg/kg, 0.3mg/kg, 0.4mg/kg ciprofol group (group A, n = 53, group B, n = 51, group C, n = 54). Mean arterial pressure (MAP), heart rate (HR), cardiac output (CO), stroke volume (SV), systemic vascular resistance (SVR), and bispectral index were recorded at the following time points: 5 minutes after entering the operating room (T<sub>0</sub>); before anesthesia induction (T<sub>1</sub>); immediately after induction (T<sub>2</sub>); 1 minute and 2 minutes after induction (T<sub>3</sub>~T<sub>4</sub>); at intubation (T<sub>5</sub>); 1 minute, 3 minutes, 5 minutes and 10 minutes after intubation (T<sub>6</sub>~T<sub>9</sub>); at skin incision (T<sub>10</sub>). The incidence of hypotension and bradycardia and the doses of vasoactive drugs were recorded.</p><p><strong>Results: </strong>Compared with T<sub>0</sub>, HR, MAP, SV, CO all decreased to varying degrees after administration, and the decrease time in Group B and Group C were earlier than that in other two groups (<i>P</i> < 0.05). SVR increased slowly after T<sub>4</sub> in all groups, but there was no significant differences (<i>P</i> > 0.05). Compared with group E, the norepinephrine dose was significantly lower in groups A and B (both <i>P</i> < 0.05). Group C showed a greater decline in CO and SV than the other three groups from T<sub>7</sub> to T<sub>10</sub> (<i>P</i> < 0.05), while there was no significant difference between groups A and E in CO and groups A, B, and E in SV (<i>P</i> > 0.05). No significant differences were observed in MAP, SVR, and the incidences of hypotension and bradycardia among the four groups (<i>P</i> > 0.05).</p><p><strong>Conclusion: </strong>0.2 mg/kg ciprofol has the least impact on hemodynamics in patients undergoing cardiac surgery, and reduced norepinephrine use.</p>","PeriodicalId":11290,"journal":{"name":"Drug Design, Development and Therapy","volume":"19 ","pages":"1671-1679"},"PeriodicalIF":4.7000,"publicationDate":"2025-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11911392/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug Design, Development and Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/DDDT.S505772","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0
Abstract
Objective: To evaluate the effects of different ciprofol doses on hemodynamics in patients undergoing cardiac surgery.
Methods: 209 patients were randomly divided into four groups: 0.2 mg/kg etomidate group (group E, n = 50), 0.2 mg/kg, 0.3mg/kg, 0.4mg/kg ciprofol group (group A, n = 53, group B, n = 51, group C, n = 54). Mean arterial pressure (MAP), heart rate (HR), cardiac output (CO), stroke volume (SV), systemic vascular resistance (SVR), and bispectral index were recorded at the following time points: 5 minutes after entering the operating room (T0); before anesthesia induction (T1); immediately after induction (T2); 1 minute and 2 minutes after induction (T3~T4); at intubation (T5); 1 minute, 3 minutes, 5 minutes and 10 minutes after intubation (T6~T9); at skin incision (T10). The incidence of hypotension and bradycardia and the doses of vasoactive drugs were recorded.
Results: Compared with T0, HR, MAP, SV, CO all decreased to varying degrees after administration, and the decrease time in Group B and Group C were earlier than that in other two groups (P < 0.05). SVR increased slowly after T4 in all groups, but there was no significant differences (P > 0.05). Compared with group E, the norepinephrine dose was significantly lower in groups A and B (both P < 0.05). Group C showed a greater decline in CO and SV than the other three groups from T7 to T10 (P < 0.05), while there was no significant difference between groups A and E in CO and groups A, B, and E in SV (P > 0.05). No significant differences were observed in MAP, SVR, and the incidences of hypotension and bradycardia among the four groups (P > 0.05).
Conclusion: 0.2 mg/kg ciprofol has the least impact on hemodynamics in patients undergoing cardiac surgery, and reduced norepinephrine use.
期刊介绍:
Drug Design, Development and Therapy is an international, peer-reviewed, open access journal that spans the spectrum of drug design, discovery and development through to clinical applications.
The journal is characterized by the rapid reporting of high-quality original research, reviews, expert opinions, commentary and clinical studies in all therapeutic areas.
Specific topics covered by the journal include:
Drug target identification and validation
Phenotypic screening and target deconvolution
Biochemical analyses of drug targets and their pathways
New methods or relevant applications in molecular/drug design and computer-aided drug discovery*
Design, synthesis, and biological evaluation of novel biologically active compounds (including diagnostics or chemical probes)
Structural or molecular biological studies elucidating molecular recognition processes
Fragment-based drug discovery
Pharmaceutical/red biotechnology
Isolation, structural characterization, (bio)synthesis, bioengineering and pharmacological evaluation of natural products**
Distribution, pharmacokinetics and metabolic transformations of drugs or biologically active compounds in drug development
Drug delivery and formulation (design and characterization of dosage forms, release mechanisms and in vivo testing)
Preclinical development studies
Translational animal models
Mechanisms of action and signalling pathways
Toxicology
Gene therapy, cell therapy and immunotherapy
Personalized medicine and pharmacogenomics
Clinical drug evaluation
Patient safety and sustained use of medicines.